The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 128)
Research Grant, 2018
There is a pressing need for Parkinson's disease (PD) biomarkers -- objective measures of disease -- that will enable early and accurate diagnosis and allow to track disease progression and therapeutic improvement. We have developed a new mathematical method to characterize PD-related brain networks. This method is based on a mathematical analysis of data collected via resting sta...
Research Grant, 2017
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease (PD). The FDA has indicated that the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) is an acceptable combined cognitive-functional outcome for use in clinical trials; however, the CDR-SOB has ...
Researchers: Daniel Weintraub, MD
Research Grant, 2017
Study Rationale & Design:
Components of blood have been found to improve health and enhance multiple biological functions in pre-clinical studies of age-related decline. Blood plasma has been particularly important in regulating the complex mechanisms that can cause these effects. The efficacy of plasma is being studied in the clinic for multiple indications. Alkahest has identified a proprietary p...
Researchers: Sam Jackson, MD, MBA
Computational Science, 2017
Analyzing Data from the Parkinson's Progression Markers Initiative to Identify Subtypes of Parkinson's Disease
Parkinson's disease (PD) presents and progresses variably, so no two people with Parkinson's have the same disease. The diversity of PD clinical manifestations makes the disease more challenging to diagnose and treat. The goal of this project is to discover Parkinson's subtypes -- patterns of disease progression -- by analyzing clinical, neuroimaging and genetic information from p...
Researchers: Fei Wang, PhD
Therapeutic Pipeline Program, 2016
Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia
Up to 80% of individuals with Parkinson's develop Parkinson's disease dementia (PDD), which is characterized by a progressive loss of memory and a decline in cognitive function. Available drugs approved to treat PDD can lessen the extent of cognitive decline caused by loss of activity in cholinergic brain circuits (chemical messenger system) to a limit...